$7.370
-0.137 (-1.86%)終値時点
JYNT のニュース
JYNT のイベント
The Joint Corp. Reports Q3 Revenue of $13.55M
Reports Q3 revenue $13.55M, consensus $14.85M. System-wide sales were $123.3M, a 3.1% decrease compared to the third quarter of 2025. "Our third quarter results reflect growth in our active membership count as well as in the lifetime value per active member," said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. "By leaning into our value proposition, especially with our newer flexible membership options, we are driving more members to stay with us longer. Primarily reflecting the ongoing macroeconomic challenges, growth in these metrics is partially offset by lower average patient spend per month and fewer new patients, which is continuing to impact our comps. We believe our ability to grow our active membership count and our stronger new clinic performance is strengthening our foundation for future growth."
The Joint Increases Stock Repurchase Authorization by $5 Million
The company said, "Our success with our clinic refranchising efforts has positioned The Joint as a pure-play franchisor model, which, combined with RD territory buybacks already completed this year, is helping to drive margin improvement, profitability and cash flow. With our strong balance sheet and improving cash generation from continuing operations, we have the financial flexibility to continue to execute simultaneously on our growth strategies, RD territory buybacks and continued stock repurchase capital allocation priorities. Our additional $5 million stock repurchase authorization reflects our confidence that our asset-light franchise model and initiatives to reignite growth will help create long-term value for our stockholders."
The Joint Corp. Reports Q2 Revenue of $15.18M
Reports Q2 revenue $15.18M, consensus $14.57M. "In the second quarter, we continued to see the benefits of our Joint 2.0 strategy take hold, with our actions to optimize the clinic portfolio, streamline our operating structure, and elevate the patient experience driving improved operating efficiency and strong free cash flow," said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. "We are encouraged with another quarter of revenue growth, as well as the improvement in comp trends compared to the first quarter. We are also seeing the early benefits of our flexible membership options, which contributed to strengthening patient retention. In addition, our national marketing initiative is leveraging consumer research to uncover emerging patient trends, ensuring our offerings align with what patients are seeking from chiropractic care."
Company Expects System-wide Sales Between $519 Million and $552 Million
The company said, "System-wide sales are expected to be between $519 million and $552 million. System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to 3%."
The Joint Corp. Q1 Revenue $14.82M, Exceeds Expectations
Reports Q1 revenue $14.82M, consensus $14.5M. "During the first quarter of 2026, we continued to build a more efficient and profitable platform, advancing our refranchising efforts, optimizing our clinic portfolio, and tightening our operating structure across the system," said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. "In April, we entered into an agreement for the sale of 45 of our company-owned or managed clinics, effectively completing our Joint 2.0 refranchising initiative, with fewer than 1% of our remaining clinic portfolio being company-owned or managed. At the same time, we remain active with our capital allocation priorities with continued share repurchases, as well as the recent completion of three regional developer buybacks that further optimize our portfolio economics."
関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。






